Navco Pharmaceuticals Inc.
NAV.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 92.59% | 93.31% | 95.00% | 95.50% | -280.45% |
| Total Depreciation and Amortization | 100.00% | 100.00% | -97.09% | -95.97% | -144.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -98.55% | -97.63% | -98.88% | -98.95% | 144.79% |
| Change in Net Operating Assets | -76.05% | -95.60% | -90.75% | -91.47% | -72.84% |
| Cash from Operations | 40.06% | 35.04% | 79.02% | 91.74% | 93.73% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -59.18% | -70.46% | -51.86% | -51.86% | 162.03% |
| Total Debt Repaid | 100.00% | 100.00% | 100.00% | 74.75% | 53.92% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -48.20% | -62.89% | -23.12% | -38.42% | 224.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.05% | -459.09% | 98.27% | 97.79% | 99.28% |